蘇州高新(600736.SH)擬公開發行不超25億元公司債券
格隆匯5月25日丨蘇州高新(600736.SH)公佈,根據《中華人民共和國公司法》、《中華人民共和國證券法》和《公司債券發行與交易管理辦法》等法律、法規和規範性文件的有關規定,經對照自查,公司符合現行公司債券監管政策和公開發行公司債券條件的各項規定,具備向專業投資者公開發行公司債券的資格。
此次債券票面金額為人民幣100元。此次發行的公司債券規模不超過人民幣25億元(含人民幣25億元),具體發行規模由股東大會授權董事會並由董事會授權董事長根據公司資金需求情況和發行時市場情況,在前述範圍內確定。
此次發行的公司債券的期限不超過5年(含5年),可以為單一期限品種,也可以為多種期限的混合品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.